Drugs / Pheripheral blood stem cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05463133 Background | Jul 2022 → Dec 2032 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pheripheral blood stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463133 ↗ |
| Modality | Cell therapy | “Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells” NCT05463133 ↗ |